Chao Ariana M, Wadden Thomas A, Berkowitz Robert I
a Department of Biobehavioral Health Sciences , University of Pennsylvania School of Nursing , Philadelphia , PA , USA.
b Department of Psychiatry , Perelman School of Medicine at the University of Pennsylvania , Philadelphia , PA , USA.
Expert Opin Drug Saf. 2018 Apr;17(4):379-385. doi: 10.1080/14740338.2018.1437143. Epub 2018 Feb 7.
Pediatric obesity is a serious public health concern. Five medications have been approved by the Food and Drug Administration (FDA) for chronic weight management in adults with obesity, when used as an adjunct to lifestyle modification. Orlistat is the only FDA-approved medication for pediatric patients aged 12 years and above.
This paper summarizes safety and efficacy data from clinical trials of weight loss medications conducted among pediatric samples. Relevant studies were identified through searches in PubMed.
Orlistat, as an adjunct to lifestyle modification, results in modest weight losses and may be beneficial for some pediatric patients with obesity. However, gastrointestinal side effects are common and may limit use. In adults taking orlistat, rare but severe adverse events, including liver and renal events, have been reported. Recent pediatric pharmacokinetic studies of liraglutide have demonstrated similar safety and tolerability profiles as found in adults, with gastrointestinal disorders being the most common adverse events. Clinical trials are needed of liraglutide, as well as other medications for obesity, that systematically evaluate their risks and benefits in pediatric patients.
儿童肥胖是一个严重的公共卫生问题。美国食品药品监督管理局（FDA）已批准五种药物用于肥胖成人的慢性体重管理，作为生活方式改变的辅助手段。奥利司他是FDA批准的唯一用于12岁及以上儿科患者的药物。
本文总结了在儿科样本中进行的减肥药物临床试验的安全性和有效性数据。通过在PubMed中检索确定了相关研究。
奥利司他作为生活方式改变的辅助手段，可使体重适度减轻，可能对一些肥胖儿科患者有益。然而，胃肠道副作用很常见，可能会限制其使用。在服用奥利司他的成人中，已报告了罕见但严重的不良事件，包括肝脏和肾脏事件。最近对利拉鲁肽的儿科药代动力学研究表明，其安全性和耐受性与成人相似，胃肠道疾病是最常见的不良事件。需要对利拉鲁肽以及其他肥胖药物进行临床试验，以系统评估它们在儿科患者中的风险和益处。
